From Tuesday 11 July to Wednesday, 12 July, AmCham EU’s Healthcare Committee visited the European Parliament in Strasbourg, France to discuss key EU health policy developments including the Parliament beginning work on the European Commission’s proposals for the revision of the general pharmaceutical legislation as well as the ongoing parliamentary negotiations on the European Health Data Space (EHDS). Meeting with key MEPs involved on these files, including rapporteurs on the EHDS and part of the pharmaceutical package, delegates underlined the need to maintain and strengthen an attractive ecosystem for life sciences innovation throughout Europe.
Diving into healthcare in Strasbourg
From Tuesday 11 July to Wednesday, 12 July, AmCham EU’s Healthcare Committee visited the European Parliament in Strasbourg, France to discuss key EU health policy developments including the Parliament beginning work on the European Commission’s proposals for the revision of the general pharmaceutical legislation as well as the ongoing parliamentary negotiations on the European Health Data Space (EHDS). Meeting with key MEPs involved on these files, including rapporteurs on the EHDS and part of the pharmaceutical package, delegates underlined the need to maintain and strengthen an attractive ecosystem for life sciences innovation throughout Europe.
During the trip, delegates met with MEPs from the main political groups including: Cristian-Silviu Buşoi (EPP, RO); Deirdre Clune (EPP, IE); Susana Solís Pérez (RE, ES); Tomislav Sokol (EPP, HR); Petar Vitanov (S&D, BG) and Pernille Weiss (EPP, DK). They also met with Bilyana Mircheva, assistant to Andrey Kovatchev (EPP, BG).
Related items
:focal())
News
20 May 2026
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Position Paper
19 May 2026
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.